Mr. David Regan reports

SONA NANOTECH CLOSES OVER-SUBSCRIBED PRIVATE PLACEMENT FINANCING TO RAISE $2,527,012 IN GROSS PROCEEDS

Sona Nanotech Inc. has closed its oversubscribed private placement that was announced on July 31, 2026, with the issuance of 8,423,372 common shares at 30 cents per share. All securities issued pursuant to the financing will be subject to a hold period of four months and one day from the date of issuance.

As previously disclosed, Sona intends to use the net proceeds of the financing for advancing studies to support the clinical advancement and continuing research and development work on its targeted hyperthermia therapy oncology treatment, as well as for general working capital purposes.

Directors of the company subscribed for 300,000 shares. Such participation is considered to be related-party transactions within the meaning of Multilateral Instrument 61-101 (Protection of Minority Security Holders in Special Transactions). The company relied on the exemptions from the formal valuation and minority shareholder approval requirements of MI 61-101 contained in sections 5.5(a) and 5.7(1)(a) of MI 61-101 in respect of related-party participation in the offering as neither the fair market value (as determined under MI 61-101) of the subject matter of, nor the fair market value of the consideration for, the transaction, insofar as it involves the related parties, exceeded 25 per cent of the company's market capitalization (as determined under MI 61-101).

About Sona Nanotech Inc.

Sona Nanotech is developing targeted hyperthermia, a photothermal cancer therapy, that uses therapeutic heat to treat solid cancer tumours. The heat is delivered to tumours by infrared light that is absorbed by Sona's gold nanorods in the tumour and re-emitted as heat. Therapeutic heat (42 to 48 C) stimulates the immune system, shrinks tumours, inactivates cancer stem cells and increases tumour perfusion, an approach aligned with the melanoma research community's active focus on converting immunogenically cold tumours, which resist immunotherapy, into hot tumours that the immune system can recognize and attack, thus enabling drugs to reach all tumour compartments more effectively. Targeted hyperthermia promises to be safe, effective, minimally invasive, competitive in cost, and a valuable adjunct to drug therapy and other cancer treatments.

Sona has developed multiple proprietary methods for the manufacture of gold nanoparticles, which it uses for the development of both cancer therapies and diagnostic testing platforms. Sona Nanotech's gold nanorod particles are cetyltrimethylammonium free, eliminating the toxicity risks associated with the use of other gold nanorod technologies in medical applications.

We seek Safe Harbor.